Ra Pharmctl Inc (RARX) Given “Buy” Rating at Jefferies Group LLC
A number of other equities research analysts have also recently commented on the company. Zacks Investment Research cut Ra Pharmctl from a buy rating to a hold rating in a report on Thursday, June 29th. Royal Bank Of Canada assumed coverage on shares of Ra Pharmctl in a research note on Thursday, September 14th. They set an outperform rating and a $21.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $26.00.
Ra Pharmctl (RARX) opened at 14.60 on Thursday. Ra Pharmctl has a 52-week low of $12.05 and a 52-week high of $24.12. The company’s 50-day moving average is $14.70 and its 200-day moving average is $14.70. The firm’s market capitalization is $330.09 million.
Ra Pharmctl (NASDAQ:RARX) last released its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06). Analysts forecast that Ra Pharmctl will post ($2.31) EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of RARX. California State Teachers Retirement System increased its position in Ra Pharmctl by 26.1% in the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $390,000 after purchasing an additional 4,300 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Ra Pharmctl by 30.6% during the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after purchasing an additional 2,543 shares in the last quarter. State Street Corp raised its stake in Ra Pharmctl by 40.3% during the second quarter. State Street Corp now owns 151,063 shares of the company’s stock valued at $2,830,000 after purchasing an additional 43,376 shares in the last quarter. Nexthera Capital LP purchased a new stake in Ra Pharmctl during the second quarter valued at $1,912,000. Finally, Fred Alger Management Inc. raised its stake in Ra Pharmctl by 83.3% during the second quarter. Fred Alger Management Inc. now owns 33,000 shares of the company’s stock valued at $618,000 after purchasing an additional 15,000 shares in the last quarter. 66.26% of the stock is owned by hedge funds and other institutional investors.
About Ra Pharmctl
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Stock Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related stocks with our FREE daily email newsletter.